230 related articles for article (PubMed ID: 32954810)
1. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
Narita Y; Shoji H; Kawai S; Mizukami T; Nakamura M; Moriwaki T; Yamanaka T; Sunakawa Y; Kawakami H; Nishina T; Misumi T; Muro K
Future Oncol; 2021 Mar; 17(8):869-875. PubMed ID: 32954810
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study.
Narita Y; Matsushima T; Sakamoto Y; Matsuoka H; Tanioka H; Kawakami T; Shoji H; Mizukami T; Izawa N; Nishina T; Yamamoto Y; Mitani S; Nakamura M; Misumi T; Muro K
ESMO Open; 2023 Dec; 8(6):102071. PubMed ID: 38016249
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
6. The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis.
He X; Zhang T; Wu L; Wu Y; Zhou X
Medicine (Baltimore); 2021 Jan; 100(2):e24110. PubMed ID: 33466182
[TBL] [Abstract][Full Text] [Related]
7. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
[TBL] [Abstract][Full Text] [Related]
8. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
9. Trifluridine/tipiracil in the treatment of gastric cancer.
Fostea RM; Arkenau HT
Future Oncol; 2022 Apr; 18(12):1511-1517. PubMed ID: 35081748
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K; Furuta M; Furusawa K; Hamaguchi T; Watanabe M; Inokuchi Y; Onuma S; Hashimoto I; Suematsu H; Nagasawa S; Kanematsu K; Yamada T; Notsu A; Ogata T; Oshima T; Machida N; Furuse J; Maeda S
Anticancer Res; 2023 Jun; 43(6):2831-2840. PubMed ID: 37247885
[TBL] [Abstract][Full Text] [Related]
11. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
[TBL] [Abstract][Full Text] [Related]
12. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
[TBL] [Abstract][Full Text] [Related]
13. Trifluridine/tipiracil for the treatment of metastatic gastric cancer.
Kawazoe A; Shitara K
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):65-70. PubMed ID: 31920125
[No Abstract] [Full Text] [Related]
14. Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer.
Arigami T; Matsushita D; Okubo K; Yanagita S; Ehi K; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Uenosono Y; Ishigami S; Natsugoe S
Oncology; 2020; 98(9):630-636. PubMed ID: 32428899
[TBL] [Abstract][Full Text] [Related]
15. [Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Hamada S; Komatsu S; Shibata R; Konishi T; Matsubara D; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2056-2058. PubMed ID: 33468799
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer.
Zhou K; Zhou J; Zhang M; Liao W; Li Q
Clin Transl Oncol; 2020 Mar; 22(3):337-343. PubMed ID: 31041716
[TBL] [Abstract][Full Text] [Related]
19. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E
Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol; 2018 Nov; 34(6):465-468. PubMed ID: 30303856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]